APA (7th ed.) Citation

YX, L., RY, W., & YL, H. (2025). Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) following atezolizumab and bevacizumab treatment for hepatocellular carcinoma. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 47(1), 13. https://doi.org/10.1007/s10072-025-08710-w

Chicago Style (17th ed.) Citation

YX, Li, Wang RY, and Hao YL. "Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) Following Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma." Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 47, no. 1 (2025): 13. https://doi.org/10.1007/s10072-025-08710-w.

MLA (9th ed.) Citation

YX, Li, et al. "Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) Following Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma." Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, vol. 47, no. 1, 2025, p. 13, https://doi.org/10.1007/s10072-025-08710-w.